Effect of L-arginine Aspartate on Plasma Hemostasis in Patients with Hypertension Stage II with Concomitant Hyperuricemia

Abstract

The prevalence of hypertension is increasing in many countries and is an important risk factor for cardiovascular morbidity and mortality. The established risk factors for hypertension include aging, dyslipidemia, and diabetes. Recently, the role of an increased level of uric acid as a risk factor for atherosclerosis, endothelial dysfunction, and hypertension has been actively studied.

The objective: аnalysis of L-arginine aspartate on the parameters of plasma hemostasis as a hemostasiological component, which reflects the severity of endothelial dysfunction in patients with hypertension stage II with concomitant hyperuricemia.

Materials and methods. We examined 74 patients (43 males and 31 females), whose average age was 55,86±6,34 years, all patients were divided into 2 groups. The first group consisted of 26 people with arterial hypertension with normal uric acid levels, the second group consisted of 34 people with hypertension and concomitant hyperuricemia, and the control group consisted of 14 healthy individuals matched for age and sex.

Results. When treating L-arginine aspartate, fibrinogen level decreased by 17,9% (p=0,05) in hypertensive patients and by 25,4% (p<0,001) in hypertensive patients with concomitant hyperuricemia, thrombin time increased in patients I groups by 40,2% (p<0,001), in group II by 65,8% (p<0,001), an increase in soluble fibrin monomer complexes is observed in all groups of patients: in the group of hypertensive patients without hyperuricemia by 39,2% (p<0,001), with combined pathology by 34,6% (p<0,001) in comparison with the baseline indicators of these patient groups. On the part of the anticoagulant system, we observed an increase in the level of antithrombin III by 27,3% (p<0,01) in hypertensive patients and by 23,4% (p<0,01) in patients with combined pathology, an increase in the level of protein C by 8,99% (p<0,05) in group I patients and 11,26% (p<0,01) in group II patients. Indicators of the fibrinolytic system of blood such as Hageman-dependent fibrinolysis decreased by 33,8% (p<0,001) in group I of patients and by 32,1% in group II of patients, plasminogen in group I increased by 22,6% (p<0,01) and in group II by 27,8% (p<0,001).

Conclusion. The use of L-arginine aspartate in patients with hypertension stage II in combination with hyperuricemia, as a secondary prevention, provides improved plasma hemostasis and has an indirect effect on the activity of inflammation as a component of the cardiovascular continuum.